GlaxoSmithKline, tha largest drugmaker in Britain, announced on Monday that the company as filed its new three-in-one inhaled lung drug for U.S. approval. The triple inhaler is being developed with Innoviva, and combines fluticasone, umeclidinium and vilanterol. If successful, the company could have the drug hit the market before its rivals in 2017. Both AstraZeneca … Continue reading “GlaxoSmithKline (GSK) Filed To Get U.S. Approval For Triple Lung Drug”
